249 related articles for article (PubMed ID: 33293369)
1. Site specificity determinants for prelamin A cleavage by the zinc metalloprotease ZMPSTE24.
Babatz TD; Spear ED; Xu W; Sun OL; Nie L; Carpenter EP; Michaelis S
J Biol Chem; 2021; 296():100165. PubMed ID: 33293369
[TBL] [Abstract][Full Text] [Related]
2. Defining substrate requirements for cleavage of farnesylated prelamin A by the integral membrane zinc metalloprotease ZMPSTE24.
Wood KM; Spear ED; Mossberg OW; Odinammadu KO; Xu W; Michaelis S
PLoS One; 2020; 15(12):e0239269. PubMed ID: 33315887
[TBL] [Abstract][Full Text] [Related]
3.
Spear ED; Hsu ET; Nie L; Carpenter EP; Hrycyna CA; Michaelis S
Dis Model Mech; 2018 Jul; 11(7):. PubMed ID: 29794150
[TBL] [Abstract][Full Text] [Related]
4. Requirements for efficient proteolytic cleavage of prelamin A by ZMPSTE24.
Barrowman J; Hamblet C; Kane MS; Michaelis S
PLoS One; 2012; 7(2):e32120. PubMed ID: 22355414
[TBL] [Abstract][Full Text] [Related]
5. The farnesyl transferase inhibitor (FTI) lonafarnib improves nuclear morphology in ZMPSTE24-deficient fibroblasts from patients with the progeroid disorder MAD-B.
Odinammadu KO; Shilagardi K; Tuminelli K; Judge DP; Gordon LB; Michaelis S
Nucleus; 2023 Dec; 14(1):2288476. PubMed ID: 38050983
[TBL] [Abstract][Full Text] [Related]
6. A humanized yeast system to analyze cleavage of prelamin A by ZMPSTE24.
Spear ED; Alford RF; Babatz TD; Wood KM; Mossberg OW; Odinammadu K; Shilagardi K; Gray JJ; Michaelis S
Methods; 2019 Mar; 157():47-55. PubMed ID: 30625386
[TBL] [Abstract][Full Text] [Related]
7. Abolishing the prelamin A ZMPSTE24 cleavage site leads to progeroid phenotypes with near-normal longevity in mice.
Wang Y; Shilagardi K; Hsu T; Odinammadu KO; Maruyama T; Wu W; Lin CS; Damoci CB; Spear ED; Shin JY; Hsu W; Michaelis S; Worman HJ
Proc Natl Acad Sci U S A; 2022 Mar; 119(9):. PubMed ID: 35197292
[TBL] [Abstract][Full Text] [Related]
8. Prelamin A and ZMPSTE24 in premature and physiological aging.
Worman HJ; Michaelis S
Nucleus; 2023 Dec; 14(1):2270345. PubMed ID: 37885131
[TBL] [Abstract][Full Text] [Related]
9. Human CaaX protease ZMPSTE24 expressed in yeast: Structure and inhibition by HIV protease inhibitors.
Clark KM; Jenkins JL; Fedoriw N; Dumont ME
Protein Sci; 2017 Feb; 26(2):242-257. PubMed ID: 27774687
[TBL] [Abstract][Full Text] [Related]
10. The structural basis of ZMPSTE24-dependent laminopathies.
Quigley A; Dong YY; Pike AC; Dong L; Shrestha L; Berridge G; Stansfeld PJ; Sansom MS; Edwards AM; Bountra C; von Delft F; Bullock AN; Burgess-Brown NA; Carpenter EP
Science; 2013 Mar; 339(6127):1604-7. PubMed ID: 23539603
[TBL] [Abstract][Full Text] [Related]
11. Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome.
Mallampalli MP; Huyer G; Bendale P; Gelb MH; Michaelis S
Proc Natl Acad Sci U S A; 2005 Oct; 102(40):14416-21. PubMed ID: 16186497
[TBL] [Abstract][Full Text] [Related]
12. ZMPSTE24, an integral membrane zinc metalloprotease with a connection to progeroid disorders.
Barrowman J; Michaelis S
Biol Chem; 2009 Aug; 390(8):761-73. PubMed ID: 19453269
[TBL] [Abstract][Full Text] [Related]
13. Human ZMPSTE24 disease mutations: residual proteolytic activity correlates with disease severity.
Barrowman J; Wiley PA; Hudon-Miller SE; Hrycyna CA; Michaelis S
Hum Mol Genet; 2012 Sep; 21(18):4084-93. PubMed ID: 22718200
[TBL] [Abstract][Full Text] [Related]
14. A homozygous ZMPSTE24 null mutation in combination with a heterozygous mutation in the LMNA gene causes Hutchinson-Gilford progeria syndrome (HGPS): insights into the pathophysiology of HGPS.
Denecke J; Brune T; Feldhaus T; Robenek H; Kranz C; Auchus RJ; Agarwal AK; Marquardt T
Hum Mutat; 2006 Jun; 27(6):524-31. PubMed ID: 16671095
[TBL] [Abstract][Full Text] [Related]
15. Prelamin A endoproteolytic processing in vitro by recombinant Zmpste24.
Corrigan DP; Kuszczak D; Rusinol AE; Thewke DP; Hrycyna CA; Michaelis S; Sinensky MS
Biochem J; 2005 Apr; 387(Pt 1):129-38. PubMed ID: 15479156
[TBL] [Abstract][Full Text] [Related]
16. Mass spectrometry captures off-target drug binding and provides mechanistic insights into the human metalloprotease ZMPSTE24.
Mehmood S; Marcoux J; Gault J; Quigley A; Michaelis S; Young SG; Carpenter EP; Robinson CV
Nat Chem; 2016 Dec; 8(12):1152-1158. PubMed ID: 27874871
[TBL] [Abstract][Full Text] [Related]
17. A Quantitative FRET Assay for the Upstream Cleavage Activity of the Integral Membrane Proteases Human ZMPSTE24 and Yeast Ste24.
Hsu ET; Vervacke JS; Distefano MD; Hrycyna CA
Methods Mol Biol; 2019; 2009():279-293. PubMed ID: 31152411
[TBL] [Abstract][Full Text] [Related]
18. LMNA mutations resulting in lipodystrophy and HIV protease inhibitors trigger vascular smooth muscle cell senescence and calcification: Role of ZMPSTE24 downregulation.
Afonso P; Auclair M; Boccara F; Vantyghem MC; Katlama C; Capeau J; Vigouroux C; Caron-Debarle M
Atherosclerosis; 2016 Feb; 245():200-11. PubMed ID: 26724531
[TBL] [Abstract][Full Text] [Related]
19. Prelamin A processing, accumulation and distribution in normal cells and laminopathy disorders.
Casasola A; Scalzo D; Nandakumar V; Halow J; Recillas-Targa F; Groudine M; Rincón-Arano H
Nucleus; 2016; 7(1):84-102. PubMed ID: 26900797
[TBL] [Abstract][Full Text] [Related]
20. Type B mandibuloacral dysplasia with congenital myopathy due to homozygous ZMPSTE24 missense mutation.
Ben Yaou R; Navarro C; Quijano-Roy S; Bertrand AT; Massart C; De Sandre-Giovannoli A; Cadiñanos J; Mamchaoui K; Butler-Browne G; Estournet B; Richard P; Barois A; Lévy N; Bonne G
Eur J Hum Genet; 2011 Jun; 19(6):647-54. PubMed ID: 21267004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
